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ABSTRACT
Invasive non-typhoidal Salmonella (iNTS) disease has emerged as a major public health concern. Yet,
understanding of the global burden is incomplete, limited particularly by the breadth of blood culture-
based surveillance systems that are able to accurately diagnose the etiology of bacteremia. The
accessibility of whole genome sequencing has allowed for genetic characterization of pathogens,
shedding light on its evolutionary history and sounding alerts for its future progression. iNTS disease
is observed to be a particular threat in sub-Saharan Africa, with a case fatality rate greatly exceeding that
of typhoid fever, and commonly affecting infants, young children and immunocompromised adults.
While iNTS disease might also be a threat in Asia and Latin America, its burden is not well characterized,
primarily owing to the lack of comprehensive reporting in these regions. Drug-resistant Salmonella
enterica (S. enterica) serovars (e.g. Typhimurium sequence type 313 (ST313)) have emerged as a potential
consequence of sustained antibiotic pressure. Genetic analyses have identified distinguished iNTS
disease-causing strains that are particularly virulent in certain human host populations. Effective treat-
ment strategies, including vaccination, are necessary; iNTS vaccines targeting the most common S.
enterica serovars, Typhimurium, Enteritidis and Dublin, are currently in early developmental stages.
Funding and political support is needed to promote vaccine development and implementation pro-
grams to ultimately reduce the threat of iNTS disease in high risk areas.
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Non-typhoidal Salmonella (NTS) serovars have an expansive
host range, and human infection by these organisms generally
results in self-limiting diarrheal disease.1 Estimates suggest
that NTS is responsible for 93 million enteric infections and
155,000 associated deaths annually.1 Additionally, certain
NTS serovars are a major cause of bloodstream infections in
specific geographical regions, posing a particular threat to
those that are HIV or malaria-infected.2 Invasive NTS
(iNTS) disease is not typically associated with diarrhea but is
accompanied by clinical features comparable to other non-
specific febrile illnesses, such as typhoid fever, and includes
symptoms of fever, hepatosplenomegaly and respiratory
symptoms.3–4 If left untreated, iNTS disease is often fatal.3–4
Immunocompromised individuals, including those infected
with HIV and malaria, and infants and young adults living
in areas where malnutrition is common, are particularly at
risk of acquiring iNTS disease.1–5 The Salmonella enterica
(S. enterica) serovars most commonly associated with iNTS
are S. Typhimurium, S. Enteritidis, and S. Dublin.3,4 The
rising magnitude of iNTS disease has only become acutely
apparent in recent decades, which may reflect a change in
epidemiology or the parallel emergence of more precise
reporting during this period.5 A summary of recent studies
reporting this disease can provide a better picture of the
spread and magnitude of the burden of iNTS disease.
Epidemiology
Invasive NTS (iNTS) disease has been highly reported in parts
of sub-Saharan Africa.3,4,6,7 However, there is a general pau-
city of data regarding the incidence of iNTS disease in many
other regions. The lack of data stems largely from the diffi-
culty to accurately diagnose the disease, as this requires
laboratories capable of microbiology and trained technicians,
both of which are challenging to maintain in resource-limited
settings. Ao et al. estimated the global burden of iNTS disease
to be 3.4 million cases and 681,316 deaths annually, with
almost 2/3 (63.7%) of all cases occurring in children under
the age of five.5 This study also estimated the incidence of
iNTS disease at a regional level. Sub-Saharan Africa and
Europe were calculated to have the highest incidences of
iNTS disease, with 227 and 102 cases of iNTS per 100,000
population, respectively. Further investigation of the unpre-
dictably high incidence originating from Europe revealed that
this was primarily driven by cases from Russia, the Ukraine,
and Estonia, which had considerably higher incidences than
Western European countries. Notably, the Americas and
Southeast Asia had considerably lower incidences of iNTS
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disease (23 and 21 cases/100,000 population, respectively) and
the Middle East and North Africa were jointly found to have
almost negligible incidence of 0.8 cases/100,000 population.5
The World Health Organization (WHO) along with Kirk
et al. further assessed the geographical distribution of iNTS
disease (Figure 1).6–7 These data do not stem from country-
level assessments, but rather from WHO regional-level cate-
gorization. Kirk et al. constructed a random effect log linear
model to estimate the global iNTS incidence.7 Due to the
scarcity of data, incidences were predicted for all ages, and
age-specific incidence rates were derived based on age profiles
for iNTS disease cases in low (i.e. United States) and high (i.e.
Mali) burden settings.5 According to this approach, iNTS
disease is more prevalent in Africa in comparison to other
parts of the world. However, while these modelled data are
helpful in understanding the geographical variation of the
disease, the sources of data were sparse, resulting in the use
of predicted incidences within some age groups.
More accurate burden estimates of iNTS disease, especially
in young children and infants, have only recently become
available through population-based surveillance aided by
whole genome sequencing to better characterize NTS
pathogens.3 Further studies are aimed at elucidating the
underlying causes of the apparent geographic distribution of
iNTS, where potential associations include environmental risk
factors and gaps in surveillance infrastructure that mask the
presence of iNTS in areas with limited diagnostics or
surveillance.
A review focusing specifically on Africa comprehensively
reported the burden of iNTS disease by building on the efforts
of Ao et al, which restricted their analysis to 14 incidence
reports alone, to obtain a more extensive picture of the epi-
demiology of iNTS disease in Africa from 1966 to 2014.4 A
total of 176 studies explicitly reporting NTS isolated by blood
culture were included, where studies ranged from longitudi-
nal, community-based surveillance to reports of isolates
obtained from patients in a hospital or community setting.
Information regarding incidence were extracted directly and
summarized according to their specific sub-group classifica-
tion, the study location, the subjects included in the study and
the time frame of the study. Published case fatality rates
(CFR) were extracted when available and the proportion of
bacteremia caused by NTS was calculated. They observed that
iNTS disease was focal, with the prevalence of community-
acquired bacteraemia associated with iNTS disease ranging
from 8% in South Africa and Nigeria to 45% in the Central
African Republic.4 They additionally found that the earliest
reported cases of iNTS disease in Africa dated back to the
mid-1960s but 55.7% of all available reports were published
between 2005 and 2014, with a peak of 18 reports in 2011. By
2014, iNTS disease had been reported in 33 countries across
five geographical regions in Africa, with 53% of the reports
originating from Eastern Africa.4 iNTS disease incidences
were extracted from 14 studies and varied between 1.4/
100,000 person-years of observation (PYO) in South Africa,
to 855/100,000 PYO in southwest Uganda for people of all
ages, where the estimated incidences were the highest among
those infected with HIV, those with sickle cell disease, and
children.4 The highest reported incidence of 2,520/100,000
PYO in children under 5 years of age was localized to rural
Ghana.4 Extractable CFR data was available from 24 of the
included studies, leading to an estimate of an average case
Figure 1. Disability-adjusted life years (DALYs) due to iNTS disease (2010).
NOTE. Estimates only available at WHO regional-level; map should not be interpreted at the country-level. The full list of the WHO regional categorization (available in ref. 6)
The DALY estimates may be conservative due to the exclusion of HIV infected individuals in the analysis.7
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fatality rate of 20.6%. This estimate is in accordance with
previous observations and was considerably higher than that
of the global estimate of CFR for typhoid fever (1%), most
likely owing to the fact that the iNTS disease burden is
concentrated in vulnerable populations, including young chil-
dren with co-morbidities.4 In sub-Saharan Africa, iNTS dis-
ease exhibits a CFR between 20 to 25% and the prevalence of
disease is associated with the concurrent endemicity of
malaria, a potential risk factor for infection.8 Ultimately,
these statistics serve the greater purpose of outlining the
nature of the threat of iNTS disease in Africa, particularly in
sub-Saharan Africa. However, despite the comprehensive nat-
ure of these studies, there was a dearth of information from
specific regions of Africa, including West Africa. Because
countries neighboring West African nations reported cases
of iNTS, the lack of published data in West Africa is likely
not due to a lack of disease burden but rather the lack of
reporting.
To address these gaps in epidemiological data on iNTS
disease and the lack of standardized population-based inci-
dence studies in sub-Saharan Africa, the Typhoid Fever
Surveillance in Africa Program (TSAP), a multi-country
investigation of the burden of invasive bacterial pathogens
(particularly typhoid fever and iNTS disease) was conducted
from 2010 to 2014.9–10 Population-based surveillance yielded
disease incidence estimates from 13 sites in 10 sub-Saharan
African countries.10 Out of all isolated bacteria from blood
from patients recruited in all countries, 17% (94/568) were
NTS isolates. The overall adjusted incidence rate (AIR) of
iNTS disease per 100,000 PYO varied between 0 in Ethiopia,
Sudan, Madagascar, and South Africa to 237 in Burkina Faso.
Notably, the incidence was generally higher in febrile patients
aged less than 5 years11. Similarly, AIR rates were specifically
higher among infants and young children, with incidences
varying between 291/100,000 PYO in Guinea-Bissau to
1,733/100,000 PYO in Ghana in children <2 years of age,
confirming previous studies suggesting a higher burden of
iNTS disease in young children and contradicting the precon-
ceived notion that iNTS disease shared a similar risk profile
with other invasive bacterial infections.10,11 Particularly note-
worthy was the observation of an association between iNTS
disease and P. falciparum malaria, where higher iNTS disease
incidence was found in areas where P. falciparum malaria was
endemic.2 The association with malaria was further strength-
ened by a case-control study conducted in two Ghanaian
hospitals.12 Additionally, in Ghana, a higher incidence of
disease was also identified in children from rural locations,
as opposed to urban settings.13 Data from the TSAP study, in
conjunction with other reports, underscore the previously
overlooked burden of iNTS disease in the African region
and the associated risk factors.
The threat of iNTS disease extends to other WHO regions
beyond Africa, albeit to a lesser extent. Previously, little inves-
tigation into the burden of iNTS disease in Asia outside of the
context of typhoid fever had been conducted. One large-scale
population-based fever surveillance study conducted in five
Asian countries reported only six iNTS disease cases out of
20,537 enrolled patients with fever.14 By site, the incidence of
iNTS disease ranged between 1.0/100,000 PYO in North
Jakarta, Indonesia and 1.8/100,000 PYO in Kolkata, India,
across all age groups.14 The highest incidence reported was
found in Karachi, Pakistan, with an incidence of 7.2/100,000
PYO among 2–15 years olds.14 Recent smaller scale studies
have additionally investigated the burden of iNTS disease in
Southeast Asian countries. A study characterizing clinical
samples collected from human populations, specifically work-
ers with occupations in the meat-handling industry, found
34.6% and 47.4% of samples collected to be positive for
Salmonella in Thailand and the Lao People’s Democratic
Republic, respectively.15 In addition to this high prevalence
of Salmonella, further molecular characterization of these
Salmonella isolates revealed S. Typhimurium to be the most
common serotype (34% of isolates in Thailand and 20.6% of
isolates in the Lao PDR), hinting at the potential threat of
iNTS disease in these regions. A more recent study conducted
in the Lao People’s Democratic Republic utilized multi-locus
sequencing typing to characterize the NTS organisms isolated
from blood and fecal samples between 2002 and 2012.16 Here,
the authors found that S. Enteritidis, S. Typhimurium and S.
Choleraesuis accounted for >90% (58/63) of iNTS disease
cases over this period.15 Notably, S. enterica Typhimurium
sequence type (ST)19 and ST34 were isolated, corroborating
previous evidence that described these ST’s in relation to
invasive disease in Southeast Asia. A study on sepsis con-
ducted in Thailand, Indonesia and Vietnam found 20/750
(2.7%) of sepsis patients to be positive for iNTS.17 While the
prevalence of iNTS disease-causing organisms was nontrivial,
as all organisms included in this study were collected from
patients presenting to health care facilities during routine
testing or in the course of a study, the data collected was
likely not representative of the nation as a whole and the
incidence of iNTS disease could not be determined.
However, as the isolation rate of iNTS disease-causing organ-
isms was fairly low, it is likely that the burden of iNTS disease,
while not insignificant, does not rival that of sub-Saharan
Africa. These data were augmented by a study in Vietnam,
where 102 cases of iNTS disease infections were documented
between 2008 and 2013, the majority (71%) of whom were
also HIV infected.18 Cases of iNTS were retrospectively iden-
tified through confirmation from blood culture from an infec-
tious disease hospital in southern Vietnam that acts as the
main primary and secondary health care facility for the sur-
rounding local population. While iNTS infection was not as
common as compared to African settings, a mortality rate of
26% was determined, which is comparable to the estimated
CFR in Africa, where HIV infection has been shown to be
associated with iNTS disease-related death.18 However, as
children with HIV were generally referred to a pediatric
hospital that was distinct from the study site, the burden of
iNTS disease was likely underestimated among the child
populations. Regardless, this study supplied the largest
description of iNTS disease cases in Southeast Asia to date,
highlighting similarities in iNTS disease epidemiology
between Asia and Africa, where in the latter setting, iNTS
disease has been more thoroughly described. Similarly, in
Bangladesh, a CFR of 25% was observed for NTS bacteraemia
patients hospitalized between 2009 and 2013.19 In Malaysia, a
retrospective study conducted from 2001 to 2011 analyzed the
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clinical details of children aged 13 years or younger with
positive blood culture admitted to the neonatal or pediatric
wards of a government hospital situated in Selangor,
Malaysia.20 Of the aetiological agents isolated from patients
that were confirmed to have community-acquired bacteremia,
one of the most common isolates found was NTS (16.2%),
highlighting these organisms’ potential to be a major public
health concern.20 Collectively, these reports are suggestive of
the endemicity of iNTS disease in parts of South and
Southeast Asia where iNTS has previously been overlooked,
and encourage future efforts to establish surveillance to moni-
tor the presence of iNTS disease-causing organisms and the
necessity for vaccines as a preventative measure.
In Latin America, however, there is a severe lack of under-
standing of the burden of iNTS due to the absence of a
systematic large-scale surveillance in this region. In
Colombia, a surveillance study conducted over a 6-year period
investigated S. enterica isolates collected from blood and fae-
cal samples and identified 32.5% of these isolates to be S.
Typhimurium.21 Of the 1,302 S. Tyhpimurium isolates iden-
tified, 19.5% were obtained from blood culture. While this
study did provide insight into the distribution of iNTS dis-
ease-causing isolates in Columbia, there were few other stu-
dies conducted in this region, and therefore, further
standardized investigation of iNTS disease is warranted to
obtain a better estimate of the burden in this area.
Multi-drug resistance/iNTS disease phylogeny
As previously described, the Salmonella serovars Enteritidis,
Dublin and Typhimurium are most commonly associated
with iNTS disease. S. Typhimurium is known to infect multi-
ple hosts while S. Dublin is more host-adapted to humans.22
Recent investigation has suggested that multi drug-resistant
(MDR) S. enterica serovars, potentially arising due to selective
pressure from sustained antibiotic exposure, are more likely to
be the causative agents of iNTS disease.22 In rural Ghana, S.
enterica serovars associated with human infection were found
to be genetically distinct from those isolated from water well
samples in the same setting.23 This observation suggests that
the S. enterica variants associated with iNTS disease are likely
able to spread between humans through the faecal-oral route
in addition to transmission through a zoonotic reservoir. Of
particular concern is the emergence of S. Typhimurium
sequence type 313 (ST313), which has evolved to cause
more invasive disease in humans compared to other sequence
types. This clone is potentially more likely to be faecal-orally
transmitted and has acquired antimicrobial resistance (AMR)
genes producing a MDR phenotype.24–26 While ST313 is pre-
valent in Africa, a clone exhibiting a differing MDR profile
than its African counterpart has recently emerged in Brazil.27
Whole genome sequencing revealed that two lineages of
ST313 are associated with human disease and are adapted to
be specifically pathogenic in immuno-compromised humans.-
22 Additionally, S. Typhimurium sequence type 19 (ST19) is
also an emergent clone that is associated with human disease
and is chiefly found in Europe and North America.8 In vitro
experimentation, comparing the pathogenicity of ST313 and
ST19, has shown that ST313 is more efficiently phagocytosed
and more resistant to killing by human macrophages.25
Further investigation of the ST313 genome sequence revealed
that this ST contains various pseudogenes and genetic dele-
tions that show a genetic resemblance to the invasive typhoi-
dal serovars and that a single mutation in a non-coding region
accounts for the high virulence of ST313 clones isolated in
Africa.28 Specifically, in ST313, a single nucleotide poly-
morphism in the promoter region of the virulence factor
gene pgtE up-regulated its expression, which could potentially
promote bacterial survival during human infection, contribut-
ing to its pathogenicity and thereby phenotypically distin-
guishing this sequence type from ST19. Two lineages of S.
Enteritidis geographically restricted to Africa contain a viru-
lence plasmid and signatures of genome degradation, indica-
tive of differential host-adaptation28. These recent discoveries
suggest that these S. enterica serovars have adapted within
specific human host populations and have evolved to become
a more virulent and prominent cause of bloodstream
infections.
iNTS disease vaccines
With the findings that MDR-iNTS organisms are currently
responsible for a large proportion of iNTS disease infections
in endemic regions, traditional first and second-line antibio-
tics are failing to combat iNTS disease, warranting the devel-
opment of a long-lasting prevention strategy, notably vaccine
development. Until recently, little investment has been pro-
vided for this endeavor, potentially because of the perceived
lack of iNTS disease burden in regions like Asia and South
America, along with the current recess in malaria incidence.
As iNTS disease is known to be associated with P. falciparum
malaria,2,12 the decline in malaria incidence was thought to be
accompanied by a concurrent decline in iNTS disease inci-
dence. Additionally, the fact that animals are thought to be
the primary reservoir for the transmission of iNTS motivated
the primary focus on WASH measures. However, in light of
recent evidence of the higher burden of iNTS disease and its
significant CFR especially in children, several vaccines,
including live-attenuated, subunit-based and recombinant
antigen-based vaccines, are currently in development. The
majority of these vaccine candidates target S.
Typhimurium.29 However, monovalent and bivalent vaccines
targeting S. Typhimurium and S. Enteritidis are also being
developed.29 Comprehensive protection would be provided
through a Th1-mediated immunity coupled with antibody
responses, which can be elicited through live-attenuated
vaccines.30 However, these vaccines would pose a risk to
immunocompromised individuals, who are at high-risk for
iNTS disease. For these groups, a killed vaccine would be
better suited. However, while killed vaccine candidates are
believed to suppress iNTS-bacteremia during the acute phase
of infection, they generally do not result in systematic clear-
ance in infected individuals.30
Given that the burden of iNTS disease is most prevalent in
children aged <5 years, with a sustained burden in the <2 years,
vaccine integration within the Expanded Program on
Immunization (EPI) would be an efficient strategy, however,
further epidemiological evidence to guide optimal scheduling is
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required. Additonal advancements have also been made with
regards to the vaccination technology itself. These include the
development of Generalized Modules for Membrane Antigens
(GMMA) derived from genetically modified bacteria, which
allow for the more efficient delivery of NTS vaccines. This
technology results from the shedding of outer membrane pro-
teins from the aforementioned bacteria which contain surface
polysaccharides and peripheral membrane proteins in their nat-
ural conformation to stimulate the innate immune system.29
This delivery system is particularly advantageous because the
technology does not require an adjuvant, does not involve com-
plex conjugation, is fairly easy to manufacture and has the
potential for high immunogenicity, thus making it particularly
advantageous in low income settings. As seen for other vaccines
targeting multiple serovars (i.e. pneumococcal vaccines), sero-
type replacement by non-vaccine-included strains could occur.-
31–33 While there is currently no data supporting this, a trivalent
vaccine targeting S. Typhimurium/S. Dublin/S. Enteritidis
would provide protection in anticipation of such a potential
scenario. Avenues for future advancement include the develop-
ment of vaccines that simultaneously target both iNTS disease
and malaria, a technology motivated by their previously identi-
fied association.2,12 Such vaccines would be particularly relevant
in areas where both iNTS disease and malaria are endemic.24
Overall, preliminary advancements on the vaccine development
front have been made, but political and financial support is
needed to facilitate the continued development of vaccines and
implementation of vaccination campaigns to target iNTS dis-
ease, particularly in areas of high endemicity.
Conclusion
iNTS disease has proven to be a major public health concern,
especially in sub-Saharan Africa. Here, distinct S. Enteritidis
clades are circulating that can be associated with iNTS
disease.28 A potential reason for this might be their ability to
be opportunistically invasive in the presence of P. falciparum
malaria and HIV;28 hence, the disease burden is highest in
infants and young children potentially resulting in higher
CFR. Outside of Africa, other genetic lineages seem to fluc-
tuate that are potentially less invasive28 and, moreover, the
iNTS disease burden has been less investigated, particularly in
remote areas in Latin America and Asia. As such, further
investment into surveillance programs in these regions is
warranted. These studies would provide further evidence of
the associated higher risk of iNTS disease in HIV or malaria-
endemic areas. Recent analyses of S. enterica serovar genomes
have alluded to the possibility that certain de novo evolved
serovars are adapting to specific human hosts and are no
longer present in high quantities in environmental reservoirs.
This supports the observation that iNTS disease overall is
evolving, likely as a result of selective pressure imposed by
sustained antimicrobial use coupled with the presence of
immunocompromising co-factors such as HIV and P. falci-
parum malaria. As such, the development of new technolo-
gies, such as vaccines, is necessary to help curb the spread of
iNTS disease in areas of high risk.
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